Dr. Wucherpfennig will continue to be responsible for coordinating the research efforts among allparticipating labs at Harvard Medical School, the Massachusetts Institute of Technology and New YorkUniversity, and for administrative oversight of the entire program.He has worked closely with all investigators involved in this PPG during the current funding period,investigators who are presently funded by this PPG (Hafler and Ploegh) and members who joined the PPGfor this renewal (Kuchroo and Turley). The close interactions among the laboratories are facilitated by theclose involvement of Drs. Wucherpfennig, Turley, Kuchroo and Hafler in the Immunology Program atHarvard Medical School which the program members serve in many different capacities (i.e. Kuchroo &Wucherpfennig - seminar committee, Hafler & Wucherpfennig - executive committee, Turley &Wucherpfennig - graduate committee). Dr. Ploegh was until recently Director of the Immunology GraduateProgram at Harvard Medical School and remains closely involved in the activities of the program. The manyinformal interactions among the investigators greatly facilitate joint research efforts. Dr. Wucherpfennig willcontinue to collaborate with all members of this PPG and will identify new opportunities for joint researchactivities. These will be discussed at joint meetings, which in the past have emphasized the application ofnew technologies to the investigation of autoimmune diseases in both animal models and patients, asevidenced by the joint development of novel approaches by Drs. Wucherpfennig & Hafler (antigen tetramers)and Drs. Ploegh & Hafler (nanowell technology for investigation of B cell function).Dr. Wucherpfennig will also continue to be in charge of all administrative aspects, and will be assisted by hisadministrator (Kimberly Foemmel) and Dana-Farber administrators who specialize in grants management(Ms. Jane Macdonald) and financial management (Ms. Linda Shehu). No funding is requested for theseDana-Farber administrators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI045757-10
Application #
7433014
Study Section
Special Emphasis Panel (ZAI1-SR-I (S2))
Project Start
2008-09-15
Project End
2013-08-31
Budget Start
2008-09-15
Budget End
2009-08-31
Support Year
10
Fiscal Year
2008
Total Cost
$38,989
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Ito, Yoshinaga; Ashenberg, Orr; Pyrdol, Jason et al. (2018) Rapid CLIP dissociation from MHC II promotes an unusual antigen presentation pathway in autoimmunity. J Exp Med 215:2617-2635
Ponath, Gerald; Lincoln, Matthew R; Levine-Ritterman, Maya et al. (2018) Enhanced astrocyte responses are driven by a genetic risk allele associated with multiple sclerosis. Nat Commun 9:5337
Sumida, Tomokazu; Lincoln, Matthew R; Ukeje, Chinonso M et al. (2018) Activated ?-catenin in Foxp3+ regulatory T cells links inflammatory environments to autoimmunity. Nat Immunol 19:1391-1402
Cremasco, Viviana; Astarita, Jillian L; Grauel, Angelo L et al. (2018) FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cancer Immunol Res 6:1472-1485
Meyer Zu Horste, Gerd; Przybylski, Dariusz; Schramm, Markus A et al. (2018) Fas Promotes T Helper 17 Cell Differentiation and Inhibits T Helper 1 Cell Development by Binding and Sequestering Transcription Factor STAT1. Immunity 48:556-569.e7
Gee, Marvin H; Sibener, Leah V; Birnbaum, Michael E et al. (2018) Stress-testing the relationship between T cell receptor/peptide-MHC affinity and cross-reactivity using peptide velcro. Proc Natl Acad Sci U S A 115:E7369-E7378
Kim, Yong Chan; Zhang, Ai-Hong; Yoon, Jeongheon et al. (2018) Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells. J Autoimmun 92:77-86
Gierahn, Todd M; Wadsworth 2nd, Marc H; Hughes, Travis K et al. (2017) Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. Nat Methods 14:395-398
Lucca, Liliana E; Hafler, David A (2017) Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev 276:9-25
Verbeke, Catia S; Gordo, Susana; Schubert, David A et al. (2017) Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation. Adv Healthc Mater 6:

Showing the most recent 10 out of 129 publications